Nutritional Supplement and Bone Health in Post-Menopausal Women

Osteoporosis, Postmenopausal Clinical Trial

— MBPS  

Official title:

Evaluation of a Milk-Based Nutritional Supplement to Modify Diurnal Rates of Bone Turnover and Effect a Positive Change in Bone Health in Post-Menopausal Women at Risk of Osteoporosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03337971
• Other study ID #: IP2016_0476
• Secondary ID: IP2016_0476
• Status: Recruiting
• Phase: N/A
• First received: October 12, 2017
• Last updated: November 6, 2017
• Start date: October 3, 2017
• Est. completion date: April 4, 2019

Study information

• Verified date: November 2017
• Source: University of Limerick
• Contact: Philip M Jakeman, PhD
• Phone: +35361202800
• Email: phil.jakeman[@]ul.ie
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone health. A balanced rate of bone resorption is required to maintain bone health, a balance that can be disturbed during the lifecycle to effect net rate of formation (as occurs during growth and development to adulthood) or net resorption (as occurs, for example, during the menopause).The research to be undertaken investigates the pluripotent effect of dairy-based products on the regulation of the diurnal process of bone metabolism in post-menopausal women at risk of osteoporosis.

Description:

Study Design: A block randomised, cross-over design of 24h rates of bone turnover in healthy, post-menopausal women with osteopenia receiving either a milk-based protein supplement (MBPS) or isoenergetic placebo control (PLACEBO).

Participants: 16 Post-menopausal women with osteopenia as determined by site-specific bone mineral density BMD (DXA) diagnosed and screened by a clinician and for dietary intake of calcium and Vit D by a clinical dietitian.

Subject screening (clinical examination) and dietary intake of calcium and Vit D (by food frequency questionnaire) will precede the experimental protocol.

Experimental protocol and data collection:

Subjects will attend for a 2 day and 2 night (overnight) residence equipped to conduct residential human trials.

The subjects' programmed protocol is as follows;

1. Arrive @ 17:00h with overnight bag;

2. Empty bladder and then provide and retain urine samples for the duration of the stay (assisted collection by researchers);

3. Consume a standardised evening meal (pre-prepared by the research dietitian) and then relax reading/watching films etc;

4. At 20:00h a research nurse will insert a cannula into a superficial arm vein and a blood draw (5ml) will be taken and processed for later analysis;

5. Further blood draws (5ml) will be taken at 22:00h, 2300h, 2400h,0100h and 0200h and the cannula withdrawn;

6. At 22:00h consume either placebo control (PLACEBO) (day 1) OR supplement (MBPM)(day 2) - or vice versa - in randomised order.

7. Retire to bedroom;

8. Consume a standardised breakfast and lunch (pre-prepared by the research dietitian) whilst living in and around the University grounds (i.e. in close proximity to ensure 24h urine collection is complete);

9. Repeat from 2 above to end of 2nd day.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: April 4, 2019
• Est. primary completion date: December 28, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

Post-menopausal women aged 50-70y. Assessed by site-specific BMD to be osteopenic. Assessed by clinical screen to be otherwise healthy and free from other illness or current medication likely to influence the study outcome.

Exclusion Criteria:

Intolerance to dairy-based food products

Related Conditions & MeSH terms

• Bone and Bones
• Osteoporosis
• Osteoporosis Risk
• Osteoporosis, Postmenopausal

Intervention

Dietary Supplement:
• PLACEBO
A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
• MBPM
A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland

Locations

Country	Name	City	State
Ireland	University of Limerick	Limerick	Co Limerick

Sponsors (2)

Lead Sponsor	Collaborator
University of Limerick	Dairygold Cooperative Society Ltd

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bone turnover	A balance of the difference between the magnitude and time course of the acute change (0-4h) in serum C-terminal telopeptide of type 1 collagen (CTX) in ng/mL, a measure of bone resorption, and procollagen type 1 amino-terminal propeptide (P1NP) in ng/ml, a measure of bone formation and diurnal change in bone resorption measured by 24h urinary excretion of deoxypyridinoline (Dpd), a marker of bone resorption, normalised to creatinine. Units nmolDPD/mmolCr	Pre-ingestion and1,2,3 and 4hours post-ingestion (serum) and Pre-ingestion to +24hour post-ingestion (urine)
Secondary	Change in regulator of bone metabolism - PTH	The magnitude and time course of the acute change (0-4h) in serum parathyroid hormone (PTH) measured in pmol/L	Pre-ingestion,1,2,3 and 4hours post-ingestion
Secondary	Change in regulator of bone metabolism - RANKL	The magnitude and time course of the acute change (0-4h) in serum receptor activator of the nuclear factor ?B ligand (RANKL) measured in ng/dL	Pre-ingestion,1,2,3 and 4hours post-ingestion
Secondary	Change in regulator of bone metabolism - OPG	The magnitude and time course of the acute change (0-4h) in serum receptor activator of the osteoprotegerin (OPG) measured in pg/mL	Pre-ingestion,1,2,3 and 4hours post-ingestion
Secondary	Incretin peptide (GIP)	The magnitude and time course of the acute change (0-4h) in enterogastric peptide glucose-dependent insulinotropic peptide (GIP1-42) measured in pg/mL	Pre-ingestion,1,2,3 and 4hours post-ingestion
Secondary	Incretin peptide (GLP-1)	The magnitude and time course of the acute change (0-4h) in enterogastric glucagon-like peptide-1 (GLP-17-36) measured in pg/mL	Pre-ingestion,1,2,3 and 4hours post-ingestion

External Links

•   Center for Inreventions in Inflammation Infection and Immunity